Patients treated with chemotherapy or immunosuppressives are at higher risk of influenza infection and mortality and morbidity are higher compared to healthy adults. Vaccination against the influenza virus can prevent these complications. In this study it is investigated whether vaccination during chemotherapy is effective in reaching protective serum antibody concentrations and the relation between time of vaccination (day 4 +/- 1 day versus day 16 +/- 1 day of the chemotherapy cycle).

开始日期2009-10-01

申办/合作机构

St.-Antonius-Hospital gGmbH

100 项与 Influenza virus vaccine(Crucell Holdings, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Influenza virus vaccine(Crucell Holdings, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Influenza virus vaccine(Crucell Holdings, Inc.) 相关的专利（医药）

登录后查看更多信息

项与 Influenza virus vaccine(Crucell Holdings, Inc.) 相关的文献（医药）

2024-12-31·Human Vaccines & Immunotherapeutics

Inactivated influenza virus vaccines expressing COBRA hemagglutinin elicited broadly reactive, long-lived protective antibodies

Article

作者: Shi, Hua ; Freiden, Pam ; Zhang, Xiaojian ; Ross, Ted M ; Livingston, Brandi ; Schultz-Cherry, Stacey ; Meliopoulos, Victoria ; Ge, Pan

The influenza viruses cause seasonal respiratory illness that affect millions of people globally every year. Prophylactic vaccines are the recommended method to prevent the breakout of influenza epidemics. One of the current commercial influenza vaccines consists of inactivated viruses that are selected months prior to the start of a new influenza season. In many seasons, the vaccine effectiveness (VE) of these vaccines can be relatively low. Therefore, there is an urgent need to develop an improved, more universal influenza vaccine (UIV) that can provide broad protection against various drifted strains in all age groups. To meet this need, the computationally optimized broadly reactive antigen (COBRA) methodology was developed to design a hemagglutinin (HA) molecule as a new influenza vaccine. In this study, COBRA HA-based inactivated influenza viruses (IIV) expressing the COBRA HA from H1 or H3 influenza viruses were developed and characterized for the elicitation of immediate and long-term protective immunity in both immunologically naïve or influenza pre-immune animal models. These results were compared to animals vaccinated with IIV vaccines expressing wild-type H1 or H3 HA proteins (WT-IIV). The COBRA-IIV elicited long-lasting broadly reactive antibodies that had hemagglutination-inhibition (HAI) activity against drifted influenza variants.

2024-10-01·International Journal of Infectious Diseases

Vaccine-related influenza virus B infection in a child with an undiagnosed B-cell acute lymphoblastic leukemia

Article

作者: Biffi, Alessandra ; Conciatori, Valeria ; Salata, Cristiano ; Franchin, Elisa ; Sopra, Sarah Di ; Lavezzo, Enrico ; Pietra, Giuseppe Di ; Vecchio, Claudia Del ; Castagliuolo, Ignazio ; Petris, Maria Grazia

We report a case of Influenza type B (lineage Yamagata) infection in a child who received the live attenuated influenza virus vaccine before being diagnosed with B-cell acute lymphoblastic leukemia. The patient developed a mild disease that persisted for 18 days and resolved without antiviral treatment. The prolonged infection of an attenuated virus in an immunocompromised host might pose a risk of reversion or evolution to a more pathogenic strain. Prompt prevention, identification, and monitoring of similar cases are desirable to avoid the development of severe illness, which could complicate patient management.

2024-10-01·Vaccine

A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters

Article

作者: Tompkins, S. Mark ; Loganathan, Madhumathi ; Clark, Jordan J. ; Krammer, Florian ; Kawaoka, Yoshihiro ; Vasilev, Kirill ; Neumann, Gabriele ; Tompkins, S Mark ; Gu, Chunyang ; Guan, Lizheng ; Campbell, John D. ; Clark, Jordan J ; Fan, Shufang ; Francis, Benjamin ; Hoxie, Irene ; Campbell, John D ; Yu, Dong ; Bushfield, Kaitlyn

Recombinant influenza virus neuraminidase (NA) is a promising broadly protective influenza vaccine candidate. However, the recombinant protein alone is not sufficient to induce durable and protective immune responses and requires the coadministration of immunostimulatory molecules. Here, we evaluated the immunogenicity and cross-protective potential of a recombinant influenza virus N2 neuraminidase vaccine construct, adjuvanted with a toll-like receptor 9 (TLR9) agonist (CpG 1018® adjuvant), and alum. The combination of CpG 1018 adjuvant and alum induced a balanced and robust humoral and T-cellular immune response against the NA, which provided protection and reduced morbidity against homologous and heterologous viral challenges in mouse and hamster models. This study supports Syrian hamsters as a useful complementary animal model to mice for pre-clinical evaluation of influenza virus vaccines.

100 项与 Influenza virus vaccine(Crucell Holdings, Inc.) 相关的药物交易

登录后查看更多信息